Breaking News, Collaborations & Alliances

Rani, ProGen Partner to Co-Develop & Commercialize Oral Obesity Treatment

RT-114 is an oral RaniPill capsule containing ProGen’s PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity.

Author Image

By: Charlie Sternberg

Associate Editor

Rani Therapeutics Holdings Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has entered into a definitive agreement with ProGen Co. Ltd., a South Korean clinical-stage biotech company developing next-gen long-acting, multi-specific fusion protein therapeutics, for the co-development and commercialization of RT-114, an oral RaniPill capsule containing ProGen’s PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity.   The RaniPill caps...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters